Spots Global Cancer Trial Database for A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
Official Title: A Non-randomized Phase II Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
Study ID: NCT03591666
Interventions
Study Description
Brief Summary: This is a non-randomized, phase II, open label study of anlotinib hydrochloride capsules in recurrent/metastatic adenocarcinomas of head and neck. The primary purpose of this study is to evaluate the efficacy of anlotinib.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Shanghai ninth people's hospital, Shanghai, Shanghai, China
Contact Details
Name: Guopei Zhu
Affiliation: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
